You are here

An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery.

TitleAn Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery.
Publication TypeJournal Article
Year of Publication2016
AuthorsZeng H, Guo M, Zhou T, Tan L, Chong CNok, Zhang T, Dong X, Xiang JZhaoying, Yu AS, Yue L, Qi Q, Evans T, Graumann J, Chen S
JournalCell Stem Cell
Volume19
Issue3
Pagination326-40
Date Published2016 Sep 01
ISSN1875-9777
Abstract

Genome-wide association studies (GWASs) have increased our knowledge of loci associated with a range of human diseases. However, applying such findings to elucidate pathophysiology and promote drug discovery remains challenging. Here, we created isogenic human ESCs (hESCs) with mutations in GWAS-identified susceptibility genes for type 2 diabetes. In pancreatic beta-like cells differentiated from these lines, we found that mutations in CDKAL1, KCNQ1, and KCNJ11 led to impaired glucose secretion in vitro and in vivo, coinciding with defective glucose homeostasis. CDKAL1 mutant insulin+ cells were also hypersensitive to glucolipotoxicity. A high-content chemical screen identified a candidate drug that rescued CDKAL1-specific defects in vitro and in vivo by inhibiting the FOS/JUN pathway. Our approach of a proof-of-principle platform, which uses isogenic hESCs for functional evaluation of GWAS-identified loci and identification of a drug candidate that rescues gene-specific defects, paves the way for precision therapy of metabolic diseases.

DOI10.1016/j.stem.2016.07.002
Alternate JournalCell Stem Cell
PubMed ID27524441
Grant ListR01 HL078960 / HL / NHLBI NIH HHS / United States